146 related articles for article (PubMed ID: 24714704)
1. Polycystic liver disease presenting as pruritus.
Johnson DK; Panchili S; Kolasseri S; Mavali RT
Ann Gastroenterol; 2014; 27(1):76-78. PubMed ID: 24714704
[TBL] [Abstract][Full Text] [Related]
2. Surgical management of polycystic liver disease.
Russell RT; Pinson CW
World J Gastroenterol; 2007 Oct; 13(38):5052-9. PubMed ID: 17876869
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogues for treatment of polycystic liver disease.
Gevers TJ; Drenth JP
Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
[TBL] [Abstract][Full Text] [Related]
4. Persistent pruritus as a rare and potentially serious manifestation of liver involvement in autosomal dominant polycystic kidney disease.
García-Prieto A; Torres E; Hernández A; Barbieri D; Vega A
Clin Kidney J; 2019 Jun; 12(3):380-381. PubMed ID: 31198538
[TBL] [Abstract][Full Text] [Related]
5. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease.
Hoevenaren IA; Wester R; Schrier RW; McFann K; Doctor RB; Drenth JP; Everson GT
Liver Int; 2008 Feb; 28(2):264-70. PubMed ID: 17927714
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of polycystic liver disease.
Gevers TJ; Drenth JP
Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):101-8. PubMed ID: 23296249
[TBL] [Abstract][Full Text] [Related]
7. Systematic review: the pathophysiology and management of polycystic liver disease.
Temmerman F; Missiaen L; Bammens B; Laleman W; Cassiman D; Verslype C; van Pelt J; Nevens F
Aliment Pharmacol Ther; 2011 Oct; 34(7):702-13. PubMed ID: 21790682
[TBL] [Abstract][Full Text] [Related]
8. Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1.
Reynolds DM; Falk CT; Li A; King BF; Kamath PS; Huston J; Shub C; Iglesias DM; Martin RS; Pirson Y; Torres VE; Somlo S
Am J Hum Genet; 2000 Dec; 67(6):1598-604. PubMed ID: 11047756
[TBL] [Abstract][Full Text] [Related]
9. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
10. Laparoscopic deroofing for polycystic liver disease using laparoscopic fusion indocyanine green fluorescence imaging.
Tanaka M; Inoue Y; Mise Y; Ishizawa T; Arita J; Takahashi Y; Saiura A
Surg Endosc; 2016 Jun; 30(6):2620-3. PubMed ID: 26416378
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms of Isolated Polycystic Liver Diseases.
Yu Z; Shen X; Hu C; Zeng J; Wang A; Chen J
Front Genet; 2022; 13():846877. PubMed ID: 35571028
[TBL] [Abstract][Full Text] [Related]
12. Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Zhang ZY; Wang ZM; Huang Y
World J Hepatol; 2020 Mar; 12(3):72-83. PubMed ID: 32231761
[TBL] [Abstract][Full Text] [Related]
13. Successful living donor liver transplantation for polycystic liver in a patient with autosomal-dominant polycystic kidney disease.
Takegoshi K; Tanaka K; Nomura H; Miyagi K; Taira S; Takayanagi N
J Clin Gastroenterol; 2001 Sep; 33(3):229-31. PubMed ID: 11500614
[TBL] [Abstract][Full Text] [Related]
14. [From gene to disease; hepatocystin and autosomal dominant polycystic liver disease].
Jansen JB; Morsche RH; Drenth JP
Ned Tijdschr Geneeskd; 2003 Jul; 147(29):1408-12. PubMed ID: 12894465
[TBL] [Abstract][Full Text] [Related]
15. Operative Outcomes for Polycystic Liver Disease: Results of a Large Contemporary Series.
Smith SR; Matar AJ; Polireddy K; Feltracco HA; Sarmiento JM
J Gastrointest Surg; 2023 Nov; 27(11):2444-2450. PubMed ID: 37783909
[TBL] [Abstract][Full Text] [Related]
16. Polycystic liver disease: a clinical review.
Chandok N
Ann Hepatol; 2012; 11(6):819-26. PubMed ID: 23109444
[TBL] [Abstract][Full Text] [Related]
17. Boy with autosomal recessive polycystic kidney and autosomal dominant polycystic liver disease.
Zingg-Schenk A; Caduff J; Azzarello-Burri S; Bergmann C; Drenth JP; Neuhaus TJ
Pediatr Nephrol; 2012 Jul; 27(7):1197-200. PubMed ID: 22415584
[TBL] [Abstract][Full Text] [Related]
18. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
[TBL] [Abstract][Full Text] [Related]
19. Feeding soy protein isolate and n-3 PUFA affects polycystic liver disease progression in a PCK rat model of autosomal polycystic kidney disease.
Maditz KH; Benedito VA; Oldaker C; Nanda N; Lateef SS; Livengood R; Tou JC
J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):467-73. PubMed ID: 25822773
[TBL] [Abstract][Full Text] [Related]
20. Tailoring the management of nonparasitic liver cysts.
Martin IJ; McKinley AJ; Currie EJ; Holmes P; Garden OJ
Ann Surg; 1998 Aug; 228(2):167-72. PubMed ID: 9712560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
